Literature DB >> 22508810

Defining the benefits of neoadjuvant chemotherapy for breast cancer.

Anne F Schott, Daniel F Hayes.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22508810     DOI： 10.1200/JCO.2011.41.3161

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  51 in total

1.  Neoadjuvant systemic therapy in breast cancer: use and trends in radiotherapy practice.

Authors:  T A Koulis; K Beecham; C Speers; S Tyldesley; D Voduc; C Simmons; R Olson
Journal:  Curr Oncol       Date:  2017-10-25       Impact factor: 3.677

2.  Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.

Authors:  Miguel Martín; José I Chacón; Antonio Antón; Arrate Plazaola; Elena García-Martínez; Miguel A Seguí; Pedro Sánchez-Rovira; José Palacios; Lourdes Calvo; Carmen Esteban; Enrique Espinosa; Agusti Barnadas; Norberto Batista; Angel Guerrero; Montserrat Muñoz; Estefania Romio; César Rodríguez-Martín; Rosalía Caballero; María I Casas; Federico Rojo; Eva Carrasco; Silvia Antolín
Journal:  Oncologist       Date:  2017-07-12

3.  Relationship between background parenchymal enhancement on breast MRI and pathological tumor response in breast cancer patients receiving neoadjuvant chemotherapy.

Authors:  Seon Jeong Oh; Eun Young Chae; Joo Hee Cha; Hee Jung Shin; Woo Jung Choi; Hak Hee Kim
Journal:  Br J Radiol       Date:  2018-06-05       Impact factor: 3.039

Review 4.  Harnessing benefit from targeting tumor associated carbohydrate antigens.

Authors:  Thomas Kieber-Emmons; Behjatolah Monzavi-Karbassi; Laura F Hutchins; Angela Pennisi; Issam Makhoul
Journal:  Hum Vaccin Immunother       Date:  2017-02       Impact factor: 3.452

5.  Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer.

Authors:  Wei Li; Takashi Tanikawa; Ilona Kryczek; Houjun Xia; Gaopeng Li; Ke Wu; Shuang Wei; Lili Zhao; Linda Vatan; Bo Wen; Pan Shu; Duxin Sun; Celina Kleer; Max Wicha; Michael Sabel; Kaixiong Tao; Guobin Wang; Weiping Zou
Journal:  Cell Metab       Date:  2018-05-24       Impact factor: 27.287

6.  Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population.

Authors:  Nataliya Babyshkina; Elena Malinovskaya; Stanislav Patalyak; Olga Bragina; Natalia Tarabanovskaya; Artem Doroshenko; Elena Slonimskaya; Vladimir Perelmuter; Nadejda Cherdyntseva
Journal:  Med Oncol       Date:  2014-08-20       Impact factor: 3.064

7.  Neoadjuvant endocrine treatment for breast cancer: from bedside to bench and back again?

Authors:  R R Saleh; N Bouganim; J Hilton; A Arnaout; M Clemons
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

Review 8.  Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer.

Authors:  Catherine M Kelly; Aman U Buzdar
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

9.  The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland.

Authors:  Derek Grose; David McIntosh; Nigel Jamieson; Ross Carter; Euan Dickson; David Chang; Husam Marashi; Christina Wilson; Mohammed Alfayez; Ashleigh Kerr; Roisin O'Donoghue; Lea Haskins; Fraser Duthie; Colin J McKay; Janet Graham
Journal:  J Gastrointest Oncol       Date:  2017-08

10.  Multicenter trials using ¹⁸F-fluorodeoxyglucose (FDG) PET to predict chemotherapy response: effects of differential measurement error and bias on power calculations for unselected and enrichment designs.

Authors:  Brenda F Kurland; Robert K Doot; Hannah M Linden; David A Mankoff; Paul E Kinahan
Journal:  Clin Trials       Date:  2013-10-29       Impact factor: 2.486
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.